1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARDX. Le, Sarah B. Goldberg, Isamu Okamoto et al.|Journal of Thoracic Oncology|2025Cited by 22
329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinibJonathan W. Riess, H.A. Yu, J.A. De Langen et al.|Annals of Oncology|2022Cited by 4